Patients with advanced solid tumors, lymphomas, or myeloma may be eligible for NCI-MATCH, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment.
The trial is for cancer patients who meet all of the following pre-qualifications:
To find patients who may be eligible for this trial, study leaders are collaborating with designated commercial and academic laboratories that test patients through standard tumor testing procedures. Tumor gene testing by a designated lab is the only pathway for new patients to enroll into the trial. This process applies to any cancer patient who gets tumor gene testing at one of the nearly 1100 clinical sites participating in the trial.
For more information, visit the Genomic Testing section.
Disclaimer: Personnel in clinical sites must review the master protocol for complete eligibility requirements and NOT rely upon this overview, which is not intended to be a comprehensive listing of inclusion and exclusion criteria.
NCI-MATCH, also known as National Cancer Institute-Molecular Analysis for Therapy Choice, or study EAY131, is a phase II precision medicine trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type. Such discoveries could be eligible to move on to larger, more definitive trials.
Inquiries about the NCI-MATCH (EAY131) study may be directed to:
ECOG-ACRIN Cancer Research Group
Operations Office – Boston